Adimab Obtains Series F Round

  • Feed Type
  • Date
    4/2/2012
  • Company Name
    Adimab
  • Mailing Address
    16 Cavendish Court Lebanon, NH 03766
  • Company Description
    Adimab–which stands for Antibody Discovery Maturation Biomanufacturing–is developing a platform that’s deliberately engineered to minimize and potentially eliminate third party royalties, offering a one-stop-service-shop to a select few Big Pharma partners.
  • Website
    http://www.adimab.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    Undisclosed
  • Transaction Round
    Series F
  • Proceeds Purposes
    We are accelerating the expansion of our platform to include additional applications such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.